NEW YORK (GenomeWeb News) — Exact Sciences today said it has extended a licensing agreement for its long-DNA biomarker technology, called DIA, with NorDiag.
Under the non-exclusive license, NorDiag will use the technology, which is designed to identify abnormal apoptosis at the molecular level, in its colorectal cancer-screening tests in Europe, Japan, and Australia.
The license also gives NorDiag the right to use the DIA marker to develop an in vitro diagnostic test kit.
NorDiag will pay a licensing fee and royalties for the right to use the technology, Exact said. Financial details were not disclosed.
Exact Sciences said that when the DIA marker is detected in stool samples, “multiple studies have shown both high sensitivity and specificity for the presence of colorectal cancer.”
Exact Sciences CEO Don Hardison said his company looks forward to entering other collaborations with NorDiag “to explore ways in which we may further leverage each other’s strengths, while continuing to advance stool-based DNA testing worldwide.”